Literature DB >> 15463949

Basic protocol for transepithelial nasal potential difference measurements.

Daniel Schüler1, Isabelle Sermet-Gaudelus, Michael Wilschanski, Manfred Ballmann, Michèle Dechaux, Aleksander Edelman, Martin Hug, Teresinha Leal, Jean Lebacq, Patrick Lebecque, Gérard Lenoir, Frauke Stanke, Pierre Wallemacq, Burkhard Tümmler, Michael R Knowles.   

Abstract

Transepithelial nasal potential difference (NPD) measurements assess ion conductance in the upper respiratory epithelium. NPD is useful in assisting in the diagnosis of classical and atypical cystic fibrosis (CF) and of cystic fibrosis transmembrane regulator (CFTR)-related disorders, as well as for monitoring the effect of pharmacological agents and gene transfer approaches to correct the abnormalities of ion transport in CF. The article summarizes the objectives and the principle of NPD measurements, describes a hands-on protocol of the procedure and provides quality control measures, practical hints and troubleshooting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15463949     DOI: 10.1016/j.jcf.2004.05.032

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  18 in total

Review 1.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

2.  A novel computational and structural analysis of nsSNPs in CFTR gene.

Authors:  C George Priya Doss; R Rajasekaran; C Sudandiradoss; K Ramanathan; R Purohit; R Sethumadhavan
Journal:  Genomic Med       Date:  2008-05-14

3.  A multiple reader scoring system for Nasal Potential Difference parameters.

Authors:  George M Solomon; Bo Liu; Isabelle Sermet-Gaudelus; Isabelle Fajac; Michael Wilschanski; Francois Vermeulen; Steven M Rowe
Journal:  J Cyst Fibros       Date:  2017-04-29       Impact factor: 5.482

Review 4.  Cystic fibrosis: terminology and diagnostic algorithms.

Authors:  K De Boeck; M Wilschanski; C Castellani; C Taylor; H Cuppens; J Dodge; M Sinaasappel
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

Review 5.  Atypical cystic fibrosis and CFTR-related diseases.

Authors:  Shruti M Paranjape; Pamela L Zeitlin
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 6.  Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.

Authors:  Steven M Rowe; Frank Accurso; John P Clancy
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

7.  Optical Nanosensors for in vivo Physiological Chloride Detection for Monitoring Cystic Fibrosis Treatment.

Authors:  Wenjun Di; Heather A Clark
Journal:  Anal Methods       Date:  2020-02-26       Impact factor: 2.896

8.  Cystic fibrosis, aminoglycoside treatment and acute renal failure: the not so gentle micin.

Authors:  Detlef Bockenhauer; Martin J Hug; Robert Kleta
Journal:  Pediatr Nephrol       Date:  2008-11-13       Impact factor: 3.714

Review 9.  Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Authors:  Samuel M Moskowitz; James F Chmiel; Darci L Sternen; Edith Cheng; Ronald L Gibson; Susan G Marshall; Garry R Cutting
Journal:  Genet Med       Date:  2008-12       Impact factor: 8.822

10.  CLCA4 variants determine the manifestation of the cystic fibrosis basic defect in the intestine.

Authors:  Ernst-Wolfgang Kolbe; Stephanie Tamm; Silke Hedtfeld; Tim Becker; Burkhard Tümmler; Frauke Stanke
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.